Literature DB >> 21350703

Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.

Guillaume Bouguen1, Jean-Baptiste Chevaux, Laurent Peyrin-Biroulet.   

Abstract

Inflammatory bowel diseases (IBDs) are complex and chronic disabling conditions resulting from a dysregulated dialogue between intestinal microbiota and components of both the innate and adaptive immune systems. Cytokines are essential mediators between activated immune and non-immune cells, including epithelial and mesenchymal cells. They are immunomodulatory peptides released by numerous cells and these have significant effects on immune function leading to the differentiation and survival of T cells. The physiology of IBD is becoming a very attractive field of research for development of new therapeutic agents. These include cytokines involved in intestinal immune inflammation. This review will focus on mechanisms of action of cytokines involved in IBD and new therapeutic opportunities for these diseases.

Entities:  

Keywords:  Biological therapy; Crohn’s disease; Cytokine; Inflammatory bowel disease; Pathophysiology; Ulcerative colitis

Mesh:

Substances:

Year:  2011        PMID: 21350703      PMCID: PMC3040326          DOI: 10.3748/wjg.v17.i5.547

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  103 in total

1.  Why are molecular mechanisms of immune activation important in IBD?

Authors:  Giovanni Monteleone; Flavio Caprioli
Journal:  Inflamm Bowel Dis       Date:  2008-10       Impact factor: 5.325

2.  TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation.

Authors:  Hidetoshi Takedatsu; Kathrin S Michelsen; Bo Wei; Carol J Landers; Lisa S Thomas; Deepti Dhall; Jonathan Braun; Stephan R Targan
Journal:  Gastroenterology       Date:  2008-05-07       Impact factor: 22.682

Review 3.  Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

Authors:  Javier P Gisbert; Julián Panés
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

4.  Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis.

Authors:  C Pena-Rossi; S Schreiber; G Golubovic; A Mertz-Nielsen; J Panes; D Rachmilewitz; M J Shieh; V I Simanenkov; D Stanton; H Graffner
Journal:  Aliment Pharmacol Ther       Date:  2008-09-15       Impact factor: 8.171

5.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Richard N Fedorak; Ellen Scherl; Mark R Fleisher; Seymour Katz; Jewel Johanns; Marion Blank; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-07-17       Impact factor: 22.682

6.  Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

Authors:  F Schnitzler; H Fidder; M Ferrante; M Noman; I Arijs; G Van Assche; I Hoffman; K Van Steen; S Vermeire; P Rutgeerts
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

Review 7.  Mucosal cytokine network in inflammatory bowel disease.

Authors:  Akira Andoh; Yuhki Yagi; Makoto Shioya; Atsushi Nishida; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

Review 8.  Biological therapies for inflammatory bowel diseases.

Authors:  Paul Rutgeerts; Severine Vermeire; Gert Van Assche
Journal:  Gastroenterology       Date:  2009-02-26       Impact factor: 22.682

9.  Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Authors:  Laurent Peyrin-Biroulet; Pierre Deltenre; Nicolas de Suray; Julien Branche; William J Sandborn; Jean-Frédéric Colombel
Journal:  Clin Gastroenterol Hepatol       Date:  2008-06       Impact factor: 11.382

10.  TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease.

Authors:  Bhanu P Pappu; Anna Borodovsky; Timothy S Zheng; Xuexian Yang; Ping Wu; Xingwen Dong; Shawn Weng; Beth Browning; Martin L Scott; Li Ma; Lihe Su; Qiang Tian; Pascal Schneider; Richard A Flavell; Chen Dong; Linda C Burkly
Journal:  J Exp Med       Date:  2008-04-14       Impact factor: 14.307

View more
  22 in total

1.  What's hot in inflammatory bowel disease in 2011?

Authors:  Silvio Danese
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

2.  Post-operative recurrence of Crohn's disease after definitive stoma: an underestimated risk.

Authors:  Dine Koriche; Corinne Gower-Rousseau; Charbel Chater; Alain Duhamel; Julia Salleron; Noémie Tavernier; Jean-Frédéric Colombel; Benjamin Pariente; Antoine Cortot; Philippe Zerbib
Journal:  Int J Colorectal Dis       Date:  2016-11-24       Impact factor: 2.571

3.  Correlations between TLR polymorphisms and inflammatory bowel disease: a meta-analysis of 49 case-control studies.

Authors:  Huijuan Wang; Shuhong Zhou; Jiahong Zhang; Shangwen Lei; Jing Zhou
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

Review 4.  Pathophysiological role of guanylate-binding proteins in gastrointestinal diseases.

Authors:  Nathalie Britzen-Laurent; Christian Herrmann; Elisabeth Naschberger; Roland S Croner; Michael Stürzl
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

5.  TNF-α and IFN-γ synergistically inhibit the repairing ability of mesenchymal stem cells on mice colitis and colon cancer.

Authors:  Shaoping Hu; Jiahui Yuan; Jiajia Xu; Xiaomei Li; Gongye Zhang; Qiujuan Ma; Bing Zhang; Tianhui Hu; Gang Song
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 6.  Immunogenetic biomarkers in inflammatory bowel diseases: role of the IBD3 region.

Authors:  Manuel Muro; Ruth López-Hernández; Anna Mrowiec
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

7.  NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.

Authors:  D Strøbæk; D T Brown; D P Jenkins; Y-J Chen; N Coleman; Y Ando; P Chiu; S Jørgensen; J Demnitz; H Wulff; P Christophersen
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

8.  Epimorphin(-/-) mice are protected, in part, from acute colitis via decreased interleukin 6 signaling.

Authors:  Anisa Shaker; Matthew Gargus; Julie Fink; Jana Binkley; Isra Darwech; Elzbieta Swietlicki; Marc S Levin; Deborah C Rubin
Journal:  Transl Res       Date:  2014-03-25       Impact factor: 7.012

9.  Chloride channel ClC-2 is a key factor in the development of DSS-induced murine colitis.

Authors:  Prashant Nighot; Karen Young; Meghali Nighot; Manmeet Rawat; Eui J Sung; Nitsan Maharshak; Scott E Plevy; Thomas Ma; Anthony Blikslager
Journal:  Inflamm Bowel Dis       Date:  2013-12       Impact factor: 5.325

10.  Anti-inflammatory effects of Lacto-Wolfberry in a mouse model of experimental colitis.

Authors:  David Philippe; Viral Brahmbhatt; Francis Foata; Yen Saudan; Patrick Serrant; Stephanie Blum; Jalil Benyacoub; Karine Vidal
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.